ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mechanism and Protective Effect of Smilax glabra Roxb on the Treatment of Heart Failure via Network Pharmacology Analysis and Vitro Verification

Long, Yingxin; Li, Zunjiang; Huang, Chunxia; Lu, Zhongyu; Qiu, Kuncheng; He, Meixing; Fang, Zhijian; Ding, Banghan*; Yuan, Xiaohong*; Zhu, Wei*广东省人民医院; 广州中医药大学
Frontiers in Pharmacology2022-5-23DOI: 10.3389/fphar.2022.868680
1被引23阅读
引用收藏
分享

摘要

Smilax glabra Roxb (SGR) has been widely applied alone or in combination with other Chinese herbs in heart failure (HF), but its mechanism and protective effect have not been investigated. We aimed to explore the mechanism and protective effect of SGR on the treatment of HF. Network pharmacology analysis predicted that SGR was involved in the regulation of cell proliferation, oxidation-reduction process, apoptotic process, ERK1 and ERK2 cascade, MAPK cascade, etc. Its mechanism was mainly involved in the MAPK signaling pathway, calcium signaling pathway, cardiac muscle contraction, etc. Subsequently, SGR was proved to improve cellular viability, restore cellular morphology, suppress cellular and mitochondrial ROS production, improve H2O2-induced lysosome inhibition, attenuate mitochondrial dysfunction, and protect mitochondrial respiratory and energy metabolism in H9c2 cells. SGR activated the p38MAPK pathway by decreasing the mRNA expression of AKT, PP2A, NF-KB, PP2A, RAC1, and CDC42 and increasing the mRNA expression of Jun, IKK, and Sirt1. SGR also decreased the protein expression of ERK1, ERK2, JNK, Bax, and Caspase3 and increased the protein expression of p38MAPK and Bcl-2. In addition, Istidina at the highest degree was identified in SGR via the UHPLCLTQ-Orbitrap-MSn method, and it was suggested as anti-heart failure agents by targeting SRC with molecular docking analysis. In conclusion, SGR has a protective effect on HF through cellular and mitochondrial protection via multi-compounds and multi-targets, and its mechanism is involved in activating the p38 MAPK pathway. Istidina may be possible anti-HF agents by targeting SRC.

学科与关键词

关键词
Smilax glabra Roxbheart failuremitochondrial dysfunctionnetwork pharmacology analysisUHPLC-LTQ-Orbitrap-MSn method
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-05-23
卷期
第 13 卷
页码
868680
DOI
10.3389/fphar.2022.868680
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
special foundation of Guangzhou Key Laboratory [542 202002010004]; Science and Technology Planning Project of Guangdong Province [2017B030314166]; Guangdong Provincial Hospital of Chinese Medicine Science and Technology Research Program [YN2019MJ11]; scientific research project of Guangdong Administration of Traditional Chinese Medicine [20211315]

作者

  • L

    Long, Yingxin (第一作者)

    2 · guangzhou univ chinese med

  • L

    Li, Zunjiang

    2 · guangzhou univ chinese med

查看全部 10 位作者收起作者
  • H

    Huang, Chunxia

    2 · guangzhou univ chinese med

  • L

    Lu, Zhongyu

    2 · guangzhou univ chinese med

  • Q

    Qiu, Kuncheng

    2 · guangzhou univ chinese med

  • H

    He, Meixing

    2 · guangzhou univ chinese med

  • F

    Fang, Zhijian

  • D

    Ding, Banghan (通讯)

    guangdong prov hosp

  • Y

    Yuan, Xiaohong (通讯)

    guangdong prov hosp

  • Z

    Zhu, Wei (通讯)

    guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417